Ipsen’s Cabometyx Bounces Back With Promising Pivotal Prostate Cancer Results
In Combination With Tecentriq
The French drugmaker’s tyrosine kinase inhibitor has met the progression-free survival primary endpoint in combination with Roche’s Tecentriq in a metastatic prostate cancer trial, edging closer to a large market opportunity after a trio of recent failures in other indications.
